ORIC Pharmaceuticals (ORIC) Competitors $5.26 -0.52 (-9.00%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$5.68 +0.42 (+7.98%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. ARQT, TARS, HRMY, TVTX, JANX, IRON, AGIO, APGE, MESO, and VERAShould you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. ORIC Pharmaceuticals vs. Arcutis Biotherapeutics Tarsus Pharmaceuticals Harmony Biosciences Travere Therapeutics Janux Therapeutics Disc Medicine Agios Pharmaceuticals Apogee Therapeutics Mesoblast Vera Therapeutics ORIC Pharmaceuticals (NASDAQ:ORIC) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation. Which has higher earnings and valuation, ORIC or ARQT? ORIC Pharmaceuticals has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.82-2.89Arcutis Biotherapeutics$196.54M9.75-$262.14M-$1.16-13.93 Which has more volatility and risk, ORIC or ARQT? ORIC Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Do institutionals & insiders hold more shares of ORIC or ARQT? 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.6% of ORIC Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ORIC or ARQT more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. ORIC Pharmaceuticals' return on equity of -44.54% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -44.54% -40.72% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Do analysts recommend ORIC or ARQT? ORIC Pharmaceuticals currently has a consensus target price of $18.86, indicating a potential upside of 258.50%. Arcutis Biotherapeutics has a consensus target price of $18.80, indicating a potential upside of 16.34%. Given ORIC Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe ORIC Pharmaceuticals is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media favor ORIC or ARQT? In the previous week, Arcutis Biotherapeutics had 13 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 16 mentions for Arcutis Biotherapeutics and 3 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 0.75 beat Arcutis Biotherapeutics' score of 0.72 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ORIC or ARQT? ORIC Pharmaceuticals received 1 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave ORIC Pharmaceuticals an outperform vote while only 67.62% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes7275.00% Underperform Votes2425.00% Arcutis BiotherapeuticsOutperform Votes7167.62% Underperform Votes3432.38% SummaryORIC Pharmaceuticals beats Arcutis Biotherapeutics on 12 of the 17 factors compared between the two stocks. Remove Ads Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricORIC PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$373.60M$6.73B$5.54B$7.49BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-2.896.9923.2518.07Price / SalesN/A198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book1.545.926.493.99Net Income-$100.70M$142.37M$3.21B$247.18M7 Day Performance-16.38%-9.32%-6.42%-6.42%1 Month Performance-31.15%-10.26%-0.68%-7.44%1 Year Performance-53.82%-15.08%6.05%-4.31% ORIC Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICORIC Pharmaceuticals4.0141 of 5 stars$5.26-9.0%$18.86+258.5%-53.8%$373.60MN/A-2.8980Gap DownARQTArcutis Biotherapeutics2.552 of 5 stars$17.29+1.6%$18.80+8.7%+67.8%$2.05B$196.54M-9.66150Analyst ForecastNews CoverageGap DownTARSTarsus Pharmaceuticals2.696 of 5 stars$52.36+4.8%$63.67+21.6%+38.1%$2.01B$182.95M-13.7450Positive NewsGap DownHRMYHarmony Biosciences4.3936 of 5 stars$34.24-2.9%$53.33+55.8%-2.3%$1.96B$714.73M16.23200TVTXTravere Therapeutics2.5821 of 5 stars$21.29+3.7%$30.62+43.8%+137.2%$1.89B$233.18M-5.19460Analyst ForecastNews CoverageGap DownJANXJanux Therapeutics2.1198 of 5 stars$31.74+6.0%$92.44+191.3%-25.7%$1.88B$10.59M-27.1330Gap DownIRONDisc Medicine3.1362 of 5 stars$53.70+2.8%$93.80+74.7%+50.1%$1.86BN/A-13.4930Positive NewsGap DownAGIOAgios Pharmaceuticals4.2601 of 5 stars$32.31+3.2%$56.57+75.1%-2.7%$1.85B$36.50M2.85390Short Interest ↓News CoveragePositive NewsGap DownAPGEApogee Therapeutics2.0871 of 5 stars$40.84+2.5%$92.17+125.7%-41.7%$1.84BN/A-16.8891Gap DownMESOMesoblast1.8093 of 5 stars$14.39+3.2%$18.00+25.1%+83.5%$1.83B$5.67M0.0080Analyst RevisionNews CoverageGap DownVERAVera Therapeutics2.9791 of 5 stars$27.15+0.3%$64.67+138.2%-42.6%$1.73BN/A-10.4040News CoverageGap Down Remove Ads Related Companies and Tools Related Companies Arcutis Biotherapeutics Competitors Tarsus Pharmaceuticals Competitors Harmony Biosciences Competitors Travere Therapeutics Competitors Janux Therapeutics Competitors Disc Medicine Competitors Agios Pharmaceuticals Competitors Apogee Therapeutics Competitors Mesoblast Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
